Post-Market Drug Safety Signal Disproportionality Report

Role: Lead Pharmacovigilance Data Scientist and Drug Safety Epidemiologist with expertise in post-market surveillance analytics.

Context

• Investigated Medicinal Product: {{product_name}}
• Indication Population: {{indication_cohort}}
• Surveillance Period: {{surveillance_window}}
• Spontaneous AE Dataset: {{adverse_event_extract}}
• Disproportionality Calculations: {{disproportionality_scores}}
• Applicable Framework: {{regulatory_jurisdiction}}

Task

Generate a Pharmacovigilance Signal Detection & Disproportionality Report that assesses spontaneous adverse event reports, evaluates statistical signal thresholds, and categorizes safety concerns for Safety Review Committee evaluation.

Method

1. Quantify total case volumes and unique spontaneous safety reports from {{adverse_event_extract}} across {{surveillance_window}}.
2. Review the disproportionality metrics in {{disproportionality_scores}} (e.g., PRR >= 2.0, chi-square >= 4.0, or lower bound IC > 0).
3. Map identified adverse event signals to their designated MedDRA System Organ Classes (SOC).
4. Stratify flagged signals by severity, labeling status (labeled vs. unlabeled events), and time-to-onset patterns.
5. Assess potential confounding factors such as co-medications, baseline comorbidities in {{indication_cohort}}, or reporting channel spikes.
6. Determine whether each candidate signal warrants routine surveillance, updated product labeling, or an expedited safety review under {{regulatory_jurisdiction}}.

Constraints

• MUST clearly separate confirmed statistical signals from background noise using provided metrics in {{disproportionality_scores}}.
• MUST NOT declare definitive medical causation; state findings in terms of statistical association and disproportionality.
• Maintain terminology consistent with MedDRA and {{regulatory_jurisdiction}} safety guidance.
• Keep report concise and structured under 750 words.

Output format

Format the report using the following markdown hierarchy:

Safety Signal Assessment Report: {{product_name}}

Surveillance Summary

• 3 summary points detailing reporting volume, surveillance window, and primary safety themes.

Signal Disproportionality Table

• Markdown table including Preferred Term (PT), System Organ Class (SOC), Observed Cases, Statistical Score (PRR/IC), and Signal Status (New Signal / Under Monitoring / Non-Significant).

Epidemiological & Clinical Discussion

• 2-3 focused paragraphs reviewing biological plausibility and confounding risk in {{indication_cohort}}.

Pharmacovigilance Action Plan

• Bulleted recommendations outlining regulatory reporting requirements and targeted medical review steps.

Self-review

1. Ensure all MedDRA terms and statistical measures from {{adverse_event_extract}} and {{disproportionality_scores}} match faithfully.
2. Verify that language adheres to statistical association without asserting unverified causal liability.
3. Check that regulatory action steps reflect the specified {{regulatory_jurisdiction}} standards.